Durable partial response to pembrolizumab, lenvatinib, and letrozole in a case of recurrent uterine carcinosarcoma with <i>ESR1</i> gene amplification.

Soiffer, Jenny L; Fife, Alexander J; Gadad, Shrikanth S; Laurini, Javier A; Elvin, Julia A; Isani, Sara S; Lin, Ken Y

Durable partial response to pembrolizumab, lenvatinib, and letrozole in a case of recurrent uterine carcinosarcoma with ESR1 gene amplification.

Soiffer, Jenny L; Fife, Alexander J; Gadad, Shrikanth S; Laurini, Javier A; Elvin, Julia A; Isani, Sara S; Lin, Ken Y.

Afiliação

Soiffer JL; Albert Einstein College of Medicine / Montefiore Medical Center, Department of Obstetrics & Gynecology and Women's Health, Division of Gynecologic Oncology, Bronx, NY, United States.
Fife AJ; Albert Einstein College of Medicine / Montefiore Medical Center, Department of Obstetrics & Gynecology and Women's Health, Division of Gynecologic Oncology, Bronx, NY, United States.
Gadad SS; Center of Emphasis in Cancer, Texas Tech University Health Sciences Center El Paso, El Paso, TX, United States.
Laurini JA; Albert Einstein College of Medicine / Montefiore Medical Center, Department of Pathology, Bronx, NY, United States.
Elvin JA; Department of Pathology and Diagnostic Medicine, Foundation Medicine Inc., Cambridge, MA, United States.
Isani SS; Albert Einstein College of Medicine / Montefiore Medical Center, Department of Obstetrics & Gynecology and Women's Health, Division of Gynecologic Oncology, Bronx, NY, United States.
Lin KY; Albert Einstein College of Medicine / Montefiore Medical Center, Department of Obstetrics & Gynecology and Women's Health, Division of Gynecologic Oncology, Bronx, NY, United States.

Gynecol Oncol Rep ; 54: 101426, 2024 Aug.

Article em En | MEDLINE | ID: mdl-38881561

ABSTRACT

ABSTRACT

â¢ESR1 gene amplification occurs in 7% of uterine carcinosarcoma.â¢The presence of ESR1 gene amplification in recurrent uterine carcinosarcoma may be targeted by aromatase inhibitors.â¢ESR1 gene amplification may be identified through immunohistochemical staining for estrogen receptor followed by fluorescence in situ hybridization or tumor targeted gene sequencing.

Texto completo

Adicionar na Minha BVS

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Revista: Gynecol Oncol Rep Ano de publicação: 2024 Tipo de documento: Article País de afiliação: Estados Unidos País de publicação: Holanda

Texto completo

Adicionar na Minha BVS

Imprimir

XML

PubMed Links

Buscar no Google